Markets
BUSINESS NEWS
- Market News
- Earnings
- Recalls
- Recession Watch
- Tech News
- Financial Crisis
- Madoff Scandal
- BloggingStocks
- Luxist
- Money Videos
INVESTING
- Stock Quotes
- Stock Charts
- Stock Ticker
- Currencies
- Portfolio
- Stock Screener
- Broker Center
- Mutual Fund Center
- ETF Center
- Money
- 24/7 Wall St.
- Financial Glossary
PERSONAL FINANCE AT WALLETPOP
- Bargains
- Banking
- Budget
- Calculators
- College Finance
- Community
- Credit
- Deals
- Debt
- Economizer
- Food
- Home
- Fraud
- Insurance
- Interest Rates
- Loans
- Mortgages
- Real Estate
- Recalls
- Recession
- Retirement
- Saving
- Simplification
- Specials
- Taxes
SMALL BUSINESS
Eurand to Participate in Upcoming Investor Conferences
PHILADELPHIA, PA -- (Marketwire) -- 10/28/09 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:
Event: Barclays Capital Healthcare Small Cap One on One Day
Date: Tuesday, November 10, 2009
Time: 7:30 a.m. to 4:00 p.m. CT (Individual Meetings)
Place: Graves 601 Hotel
601 First Avenue North
Minneapolis, Minn.
Event: 2009 Credit Suisse Healthcare Conference
Date: Wednesday, November 11, 2009
Time: 10:00 a.m. MT (Presentation by Eurand Chief Commercial Officer
John Fraher)
Place: Arizona Biltmore
2400 East Missouri Avenue
Phoenix, Ariz.
An audio webcast of the Company's presentation at the Credit Suisse Conference will be available by accessing the investor relations section of www.eurand.com and will be available via replay for 30 days following the date of the presentation.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1-267-759-9335
Email Contact
Nick Laudico/Sara Pellegrino
The Ruth Group
+1-646-536-7030/7002
Email Contact
Email Contact